Follow the Pundits

Tag: Funanc1alInsiders

Cartoon Ackman in Brookfield tower waving as value floats away by parachute—symbolizing Brookfield's price rise and shrinking value opportunity.

Bill Ackman’s Pershing Square Still Hearts Brookfield (BN)

Bill Ackman still loves Brookfield, his top Pershing Square bet—now up 39%! But at nearly $68 per share, has the value vanished? We dig into insider buying, institutional interest, financial highlights, and whether this former bargain is still a buy. 💼📈

Read entire article

Tags: Ackman, Bill Ackman, BN, Brookfield Corporation, Follow the Pundits, Funanc1al, Funanc1al International Investment Series, Funanc1al Opportunities Overseas, Funanc1al Stocks to Watch, Funanc1alDiversification, Funanc1alEdge, Funanc1alFinance, Funanc1alFun, Funanc1alHumor, Funanc1alInsiders, Funanc1alInsights, Funanc1alInvesting, Funanc1alStocks, Pershing Square Capital, PershingSquare, StockAnalysis, StocksToWatch, ValueInvesting
Investor hiker climbing a brain-shaped Acadia National Park trail marked by biotech milestones, symbolizing ACADIA Pharmaceuticals’ growth potential.

ACADIA Pharmaceuticals: Biotech Powerhouse Baker Bros Still Believes. Should You Buy In?

Biotech heavyweight Baker Bros still owns over 25% of ACADIA Pharmaceuticals (ACAD), and the stock is heating up. With expanding revenue, a rich CNS pipeline, and smart money backing it, is this the comeback story investors have been waiting for?

Read entire article

Tags: ACAD, ACADIA Pharmaceuticals, Baker Bros, Biotech Investing, Biotech Stocks, Funanc1al, Funanc1al Contrarian Picks, Funanc1al for Investors, Funanc1al Investing, Funanc1alBiotech, Funanc1alEdge, Funanc1alFinance, Funanc1alFun, Funanc1alHumor, Funanc1alInsiders, Funanc1alInvesting, Funanc1alMentalHealth, Funanc1alPharma, Funanc1alStocks, Growth Investing, Hedge Funds Investing, High-Conviction Investing, insider holdings, Parkinson’s disease, pharma pipeline, Rett Syndrome